Phase 1b/2a expansion trial (including indication and dose exploration) assessing the safety, efficacy and PK characteristics of QHL-108
Latest Information Update: 22 Dec 2023
At a glance
- Drugs QHL 108 (Primary)
- Indications Breast cancer; Gastric cancer; Ovarian cancer; Soft tissue sarcoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 22 Dec 2023 New trial record